Voluntary Electronic Reporting Of Postmarketing ADRs Urged By NDMA
This article was originally published in The Tan Sheet
Executive Summary
The submission of postmarketing adverse drug reaction reports through electronic means should be voluntary, not mandatory, the Nonprescription Drug Manufacturers Association maintains in Feb. 3 comments to FDA.